<SEC-DOCUMENT>0000950170-23-071111.txt : 20231218
<SEC-HEADER>0000950170-23-071111.hdr.sgml : 20231218
<ACCEPTANCE-DATETIME>20231218163047
ACCESSION NUMBER:		0000950170-23-071111
CONFORMED SUBMISSION TYPE:	4
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20231214
FILED AS OF DATE:		20231218
DATE AS OF CHANGE:		20231218

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			Cuss Francis M
		CENTRAL INDEX KEY:			0001490216
		ORGANIZATION NAME:           	

	FILING VALUES:
		FORM TYPE:		4
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-41837
		FILM NUMBER:		231494193

	MAIL ADDRESS:	
		STREET 1:		BRISTOL-MYERS SQUIBB COMPANY
		STREET 2:		ROUTE 206 & PROVINCE LINE ROAD
		CITY:			PRINCETON
		STATE:			NJ
		ZIP:			08543

ISSUER:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Mural Oncology plc
		CENTRAL INDEX KEY:			0001971543
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			L2
		FISCAL YEAR END:			1231

	BUSINESS ADDRESS:	
		STREET 1:		10 EARLSFORT TERRACE
		CITY:			DUBLIN 2
		STATE:			L2
		ZIP:			D02 T380
		BUSINESS PHONE:		353 1 905 8020

	MAIL ADDRESS:	
		STREET 1:		10 EARLSFORT TERRACE
		CITY:			DUBLIN 2
		STATE:			L2
		ZIP:			D02 T380

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Mural Oncology Ltd
		DATE OF NAME CHANGE:	20230403

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Pistachiovale Ltd
		DATE OF NAME CHANGE:	20230329
</SEC-HEADER>
<DOCUMENT>
<TYPE>4
<SEQUENCE>1
<FILENAME>ownership.xml
<DESCRIPTION>4
<TEXT>
<XML>
<?xml version="1.0"?>
<ownershipDocument>

    <schemaVersion>X0508</schemaVersion>

    <documentType>4</documentType>

    <periodOfReport>2023-12-14</periodOfReport>

    <issuer>
        <issuerCik>0001971543</issuerCik>
        <issuerName>Mural Oncology plc</issuerName>
        <issuerTradingSymbol>MURA</issuerTradingSymbol>
    </issuer>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0001490216</rptOwnerCik>
            <rptOwnerName>Cuss Francis M</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>C/O MURAL ONCOLOGY PLC</rptOwnerStreet1>
            <rptOwnerStreet2>10 EARLSFORT TERRACE</rptOwnerStreet2>
            <rptOwnerCity>DUBLIN 2</rptOwnerCity>
            <rptOwnerState>L2</rptOwnerState>
            <rptOwnerZipCode>D02 T380</rptOwnerZipCode>
            <rptOwnerStateDescription>IRELAND</rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isDirector>true</isDirector>
            <isOfficer>false</isOfficer>
            <isTenPercentOwner>false</isTenPercentOwner>
            <isOther>false</isOther>
        </reportingOwnerRelationship>
    </reportingOwner>

    <aff10b5One>false</aff10b5One>

    <derivativeTable>
        <derivativeTransaction>
            <securityTitle>
                <value>Stock Option (right to buy)</value>
            </securityTitle>
            <conversionOrExercisePrice>
                <value>3.61</value>
            </conversionOrExercisePrice>
            <transactionDate>
                <value>2023-12-14</value>
            </transactionDate>
            <transactionCoding>
                <transactionFormType>4</transactionFormType>
                <transactionCode>A</transactionCode>
                <equitySwapInvolved>false</equitySwapInvolved>
            </transactionCoding>
            <transactionAmounts>
                <transactionShares>
                    <value>15021</value>
                </transactionShares>
                <transactionPricePerShare>
                    <value>0.00</value>
                </transactionPricePerShare>
                <transactionAcquiredDisposedCode>
                    <value>A</value>
                </transactionAcquiredDisposedCode>
            </transactionAmounts>
            <exerciseDate>
                <footnoteId id="F1"/>
            </exerciseDate>
            <expirationDate>
                <value>2033-12-13</value>
            </expirationDate>
            <underlyingSecurity>
                <underlyingSecurityTitle>
                    <value>Ordinary Shares</value>
                </underlyingSecurityTitle>
                <underlyingSecurityShares>
                    <value>15021</value>
                </underlyingSecurityShares>
            </underlyingSecurity>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>15021</value>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </derivativeTransaction>
    </derivativeTable>

    <footnotes>
        <footnote id="F1">This option was granted on December 14, 2023. This option shall vest over three years in twelve equal quarterly installments on each quarterly anniversary of October 31, 2023, subject to the reporting person's continued service with the Issuer.</footnote>
    </footnotes>

    <ownerSignature>
        <signatureName>/s/ Maiken Keson-Brookes, attorney-in-fact for Francis M. Cuss</signatureName>
        <signatureDate>2023-12-18</signatureDate>
    </ownerSignature>
</ownershipDocument>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
